Kaux, J.-F., & DEROISY, R. (2024). Le PRP par aphérèse. In P. Ornetti, A. Silvestre, C. Andia, C. Darrieutort-Laffite, K. Louati, H. Collado, E. Dalmais, V. Legré-Boyer, ... H. Bard, Actualités en médecine régénérative musculosquelettique (pp. 25-31). Montpellier, France: Sauramps Médical. Editorial reviewed |
ROUSSEAU, A.-F., DEROISY, R., LECART, M.-P., MASSENET, V., SARLET, N., Misset, B., CAVALIER, E., & KAUX, J.-F. (2022). Bone health in survivors of a prolonged ICU stay. Aging Clinical and Experimental Research, 34 (S1), 332. Peer Reviewed verified by ORBi |
DEROISY, R., NEUPREZ, A., LEONARD, Y., LECART, M.-P., MASSENET, V., GILLET, P., Reginster, J.-Y., & KAUX, J.-F. (December 2020). Identification, through a Fracture Liaison Service, of undiagnosed vertebral fractures in patients hospitalized for a prevalent hip fragility fracture. Osteoporosis International, 31 (S1), 200. Peer Reviewed verified by ORBi |
NEUPREZ, A., DEROISY, R., LEONARD, Y., LECART, M.-P., MASSENET, V., GILLET, P., KAUX, J.-F., & Reginster, J.-Y. (December 2020). Secondary fracture prevention in hip fracture patients: 6-year impact of a Fracture Liaison Service. Osteoporosis International, 31 (S1), 199-200. Peer Reviewed verified by ORBi |
Kaux, J.-F., Bornheim, S., Dardenne, N., DEROISY, R., SAMSON, A., Roberjot, M., & Croisier, J.-L. (July 2019). Comparison between platelet-rich plasma injections and hyaluronic acid injections in the treatment of patellar tendinopathies: a randomized trial. Muscles, Ligaments and Tendons Journal, 9 (3), 322-327. doi:10.32098/mltj.03.2019.03 Peer Reviewed verified by ORBi |
Kaux, J.-F., SAMSON, A., DEROISY, R., Roberjot, M., & Croisier, J.-L. (2018). Platelet-rich plasma (PRP) versus hyaluronic acid injections to treat patellar tendinopathies. In Abstract Book - 21st European Congress of Physical and Rehabilitation Medicine (pp. 121). Peer reviewed |
Kaux, J.-F., DEROISY, R., SAMSON, A., Roberjot, M., Dardenne, N., & Croisier, J.-L. (January 2018). Comparison of the effect of Platelet Rich Plasma (PRP) with Hyaluronic Acid (HA) injections to treat chronic Jumper's knee. Journal of Rehabilitation Medicine, 50 (1), 109-110. Peer Reviewed verified by ORBi |
Runhaar, J., DEROISY, R., van Middelkoop, M., Barbetta, F., Barbetta, B., Oei, E. H., Vroeginddeweij, D., Giacovelli, G., Bruyère, O., Rovati, L. C., Reginster, J.-Y., & Bierma-Zeinstra, S. M. A. (2016). The role of diet and exercise and of glucosamine sulfate in the prevention of knee osteoarthritis: Further results from the PRevention of knee Osteoarthritis in Overweight Females (PROOF) study. Seminars in Arthritis and Rheumatism, 45 (4 Suppl), 42-S48. doi:10.1016/j.semarthrit.2015.11.001 Peer Reviewed verified by ORBi |
Bruyère, O., DEROISY, R., Dardenne, N., Cavalier, E., COFFINER, M., da silva, S., De Niet, S., & Reginster, J.-Y. (December 2015). A phase IV, two-armed, randomized, cross-over study comparing compliance with once-a-month administration of vitamin D3 to compliance with daily administration of a fixed-dose combination of vitamin D3 and calcium during two 6-month periods. Osteoporosis International, 26 (12), 2863-8. doi:10.1007/s00198-015-3205-z Peer Reviewed verified by ORBi |
Rabenda, V., Bruyère, O., Cavalier, E., DEROISY, R., LECART, M.-P., COLLETTE, J., & Reginster, J.-Y. (2015). Serum concentrations of osteoprotegerin (OPG) and dickkope-1 (DKK1) poorly predict bone mineral density changes and fracture incidence in postmenopausal osteoporotic women. Osteoporosis International, 26 (S1), 240. Peer Reviewed verified by ORBi |
DEROISY, R., Reginster, J.-Y., & Bruyère, O. (April 2013). Reproducibility of joint space width assessment when external calibration on the radiograph is missing. Osteoporosis International, 24 (Suppl.1), 379. Peer Reviewed verified by ORBi |
Bruyère, O., Roux, C., Nicolet, D., Fechtenbaum, J., DEROISY, R., & Reginster, J.-Y. (June 2012). Severe prevalent vertebral fractures predict subsequent vertebral and nonvertebral fractures: a 3-year prospective study. Annals of the Rheumatic Diseases, 71 (Suppl.3), 588. Peer Reviewed verified by ORBi |
Bruyère, O., Roux, C., Nicolet, D., Fechtenbaum, J., DEROISY, R., & Reginster, J.-Y. (June 2012). Severity of incident vertebral fracture and future fracture risk: a 3-year prospective study. Annals of the Rheumatic Diseases, 71 (Suppl.3), 716. Peer Reviewed verified by ORBi |
Bruyère, O., Roux, C., Nicolet, D., Fechtenbaum, J., DEROISY, R., & Reginster, J.-Y. (March 2012). Severe prevalent vertebral fractures predict subsequent vertebral and nonvertebral fractures: a 3-year prospective study. Osteoporosis International, 23 (Suppl. 2), 361-362. Peer Reviewed verified by ORBi |
Gensburger, D., DEROISY, R., Arlot, M., Bruyère, O., Chapurlat, R., & Reginster, J.-Y. (March 2012). Assessment of joint space narrowing in knee osteoarthritis has good long-term intercentre reproducibility when read in pairs with a semi-automated device. Osteoporosis International, 23 (Suppl. 2), 247-248. Peer Reviewed verified by ORBi |
Bruyère, O., Roux, C., Nicolet, D., Fechtenbaum, J., DEROISY, R., & Reginster, J.-Y. (March 2012). Severity of incident vertebral fracture and future fracture risk: a 3-year prospective study. Osteoporosis International, 23 (Suppl. 2), 60-61. Peer Reviewed verified by ORBi |
DEROISY, R., Bruyère, O., Gensburger, D., Chapurlat, R., & Reginster, J.-Y. (March 2012). Long-term (3 years) reproducibility for the radiological assessment of knee osteoarthritis. Osteoporosis International, 23 (Suppl. 2), 219-220. Peer Reviewed verified by ORBi |
DEROISY, R., Bruyère, O., & Reginster, J.-Y. (March 2011). Stable precision over time when assessing the cartilage loss on knee osteoarthritis radiograph [Paper presentation]. 1st IOF-ESCEO Pre-clinical Symposium (2011), European Congress on Osteoporosis and Osteoarthritis ECCEO11-IOF, Valencia, Spain. |
Deroisy, R., Roux, J. P., Bruyère, O., Gensburger, D., Chapurlat, R., & Reginster, J.-Y. (May 2010). Long term agreement between two different centres regarding joint space narrowing measurement in knee osteoarthritis. Osteoporosis International, 21 (Suppl.1), 233-234. Peer Reviewed verified by ORBi |
Bruyère, O., COLLETTE, J., DEROISY, R., Rabenda, V., Neuprez, A., Hiligsmann, M., & Reginster, J.-Y. (October 2009). Biochemical markers of bone and cartilage remodelling: interest in the prediction of lumbar disc degeneration progression and effects of strontium ranelate over a 3-year period. Arthritis and Rheumatism, 60 (number 10 (suppl.)), 313. Peer Reviewed verified by ORBi |
Bruyère, O., Collette, J., Deroisy, R., Rabenda, V., Hiligsmann, M., & Reginster, J.-Y. (March 2009). Prediction of spinal osteoarthritis progression by assessment of biochemical markers of bone and cartilage remodelling: a 3-year study. Osteoporosis International, 20 (Suppl.1), 8. Peer Reviewed verified by ORBi |
Bruyère, O., De Cock, C., Deroisy, R., & Reginster, J.-Y. (2009). Bone mineral density and health related quality of life: a 3-year follow-up study of osteoportic postmenopaul women. The Open Geritric Medicine Journal, 2, 44-52. Peer reviewed |
Reginster, J.-Y., Deroisy, R., NEUPREZ, A., Hiligsmann, M., Zegels, B., & Bruyère, O. (2009). Strontium ranelate: new data on fracture prevention and mechanisms of action. Current Osteoporosis Reports, 7 (3), 96-102. doi:10.1007/s11914-009-0016-1 Peer Reviewed verified by ORBi |
Bruyère, O., Collette, J., Christiansen, F., Fardellone, F., Detroz, A., Deroisy, R., & Reginster, J.-Y. (June 2008). Association between lumbar disc degeneration and biochemical markers of bone and cartilage remodelling. Annals of the Rheumatic Diseases, 67 (Suppl.II), 231. Peer Reviewed verified by ORBi |
Bruyère, O., Collette, J., Christiansen, C., Padrino, J. M., Fardellone, J. P., Detroz, A., Deroisy, R., & Reginster, J.-Y. (April 2008). Association between spinal osteoarthritis and biochemical markers of bone and cartilage remodelling. Osteoporosis International, 19 (Suppl.1), 200. Peer Reviewed verified by ORBi |
Reginster, J.-Y., Collette, J., NEUPREZ, A., Zegels, B., Deroisy, R., & Bruyère, O. (10 February 2008). Role of Biochemical Markers of Bone Turnover as Prognostic Indicator of Successful Osteoporosis Therapy. BONE, 42, 832-836. doi:10.1016/j.bone.2008.01.021 Peer Reviewed verified by ORBi |
Bruyère, O., Pavelka, K., Rovati, L. C., Gatterova, J., Giacovelli, G., Olejarova, M., Deroisy, R., & Reginster, J.-Y. (February 2008). Total Joint Replacement after Glucosamine Sulphate Treatment in Knee Osteoarthritis: Results of a Mean 8-Year Observation of Patients from Two Previous 3-Year, Randomised, Placebo-Controlled Trials. Osteoarthritis and Cartilage, 16 (2), 254-60. doi:10.1016/j.joca.2007.06.011 Peer Reviewed verified by ORBi |
COLLETTE, J., Reginster, J.-Y., Bruyère, O., DEROISY, R., Jupsin, I., Devogelaer, J.-P., Adami, S., & Marcelli, C. (May 2007). Dissociation between bone formation and bone resorption evidenced by changes in biochemical markers of bone turnover in patients treated with strontium ranelate. Calcified Tissue International, 80 (Suppl.1), 120. Peer Reviewed verified by ORBi |
Collette, J., Reginster, J.-Y., Bruyère, O., Deroisy, R., Jupsin, I., Devogelaer, J.-P., Adami, S., & Marcelli, C. (March 2007). Dissociation between bone formation and bone resorption evidenced by changes in biochemical markers of bone turnover in patients treated with strontium ranelate. Osteoporosis International, 18 (Suppl.1), 125. Peer Reviewed verified by ORBi |
Bruyère, O., Pavelka, K., Rovati, L. C., Gatterova, J., Giacovelli, G., Olejarova, M., Deroisy, R., & Reginster, J.-Y. (March 2007). Total joint replacement after glucosamine sulfate treatment of knee osteoarthritis: results from a 8-year prospective cohort. Osteoporosis International, 18 (Suppl.1), 81. Peer Reviewed verified by ORBi |
Reginster, J.-Y., COLLETTE, J., Bruyère, O., DEROISY, R., & Jupsin, I. (November 2006). Biochemical markers of bone turnover confirm the dual mode of action of strontium ranelate: increase in bone formation and decrease in bone resorption. Arthritis and Rheumatism, 54 (Suppl), 590. Peer Reviewed verified by ORBi |
MALAISE, O., Bruyère, O., Deroisy, R., Jupsin, I., & Reginster, J.-Y. (June 2006). Strontium Ranelate normalizes bone mineral density in osteopenic patients. Osteoporosis International, 17 (Suppl.2), 103. Peer Reviewed verified by ORBi |
MALAISE, O., Bruyère, O., Deroisy, R., Jupsin, I., & Reginster, J.-Y. (March 2006). Strontium Ranelate normalizes bone mineral density in osteopenic patients. Osteoporosis International, 17 (Suppl.1), 63. Peer Reviewed verified by ORBi |
Richy, F., Deroisy, R., Lecart, M.-P., Hanssens, L., Mawet, A., & Reginster, J.-Y. (April 2005). D-Hormone analog alfacalcidol: an update on its role in post-menopausal osteoporosis and rheumatoid arthritis management. Aging Clinical and Experimental Research, 17 (2), 133-142. doi:10.1007/BF03324586 Peer Reviewed verified by ORBi |
Kaufman, J.-M., DEROISY, R., Gangji, V., & Reginster, J.-Y. (March 2005). Patients prefer calcium+vitamin D3 chewable tablets (Steovit D3) above calcium+vitamin D3 effervescent powder (Cacit D3). Osteoporosis International, 16 (Suppl.3). Peer Reviewed verified by ORBi |
Richy, F., DEROISY, R., LECART, M.-P., Hanssens, L., Schacht, E., & Reginster, J.-Y. (March 2005). D-hormone analog alfacalcidol: its role in postmenopausal osteoporosis and rheumatoid arthritis management. Osteoporosis International, 16 (Suppl.3), 105-106. Peer Reviewed verified by ORBi |
Bruyère, O., Pavelka, K., Rovati, L. C., Deroisy, R., Olejarova, M., Gatterova, J., Giacovelli, G., & Reginster, J.-Y. (2004). Glucosamine sulfate reduces osteoarthritis progression in postmenopausal women with knee osteoarthritis: evidence from two 3-year studies. Menopause, 11 (2), 138-143. doi:10.1097/01.GME.0000087983.28957.5D Peer Reviewed verified by ORBi |
REGINSTER, J.-Y., LECART, M.-P., DEROISY, R., & Lousberg, C. (2004). Strontium ranelate: a new paradigm in the treatment of osteoporosis. Expert Opinion on Investigational Drugs, 13 (7), 857-64. doi:10.1517/13543784.13.7.857 Peer Reviewed verified by ORBi |
Christgau, S., Henrotin, Y., Tanko, L. B., Rovati, L. C., Collette, J., Bruyère, O., Deroisy, R., & Reginster, J.-Y. (2004). Osteoarthritic patients with high cartilage turnover show increased responsiveness to the cartilage protecting effects of glucosamine sulphate. Clinical and Experimental Rheumatology, 22 (1, JAN-FEB), 36-42. Peer Reviewed verified by ORBi |
Bruyère, O., Pavelka, K., Rovati, L. C., Deroisy, R., Olejarova, M., Gatterova, J., Giacovelli, G., & Reginster, J.-Y. (November 2003). Glucosamine sulfate reduces osteoarthritis progression in postmenopausal women with knee osteoarthritis: evidence from two large, randomised, placebo-controlled, double-blind, 3-year studies. Osteoporosis International, 14 (Suppl. 7), 62. Peer Reviewed verified by ORBi |
Bruyère, O., Compère, S., Gathy, C., Rovati, L. C., Giacovelli, G., Deroisy, R., & Reginster, J.-Y. (November 2003). Five-year follow-up patients issued from a previous 3-year randomised, controlled trial of glucosamine sulfate in knee osteoarthritis. Osteoporosis International, 14 (Suppl 7), 9. Peer Reviewed verified by ORBi |
Bruyère, O., Compere, S., Rovati, L. C., Giacovelli, G., DEROISY, R., & Reginster, J.-Y. (October 2003). Five-year follow-up of patients from a previous 3-year randomised, controlled trial of glucosamine sulfate in knee osteoarthritis. Osteoarthritis and Cartilage, 11 (Suppl.1), 10-11. Peer Reviewed verified by ORBi |
Bruyère, O., Compere, S., Rovati, L. C., Giacovelli, G., DEROISY, R., & Reginster, J.-Y. (September 2003). Five-year follow-up of patients from a previous 3-year randomised, controlled trial of glucosamine sulfate in knee osteoarthritis. Arthritis and Rheumatism, 48 (number 9 (suppl.)), 80. Peer Reviewed verified by ORBi |
Reginster, J.-Y., Deroisy, R., & Jupsin, I. (February 2003). Strontium ranelate: A new paradigm in the treatment of osteoporosis. Drugs of Today, 39 (2), 89-101. doi:10.1358/dot.2003.39.2.799416 Peer reviewed |
Reginster, J.-Y., Deroisy, R., Dougados, M., Jupsin, I., Collette, J., & Roux, C. (December 2002). Prevention of early postmenopausal bone loss by strontium ranelate: The randomized, two-year, double-masked, dose-ranging, placebo-controlled PREVOS trial. Osteoporosis International, 13 (12), 925-931. doi:10.1007/s001980200129 Peer Reviewed verified by ORBi |
Pavelka, K., Rovati, L. C., Gatterova, J., Bruyère, O., Deroisy, R., Machacek, S., Giacovelli, G., & Reginster, J.-Y. (November 2002). Pain relief is not a confounder in joint space narrowing assessment of full extension knee radiographs in osteoarthritis structure-modifying drug trials. Osteoporosis International, 13 (Suppl.3), 19-20. Peer Reviewed verified by ORBi |
Reginster, J.-Y., Rovati, L. C., Deroisy, R., Henrotin, Y., Gatterova, J., Machacek, S., Giacovelli, G., & Pavelka, K. (November 2002). Glucosamine sulfate slows-down osteoarthritis progression in postmenopausal women: pooled analysis of two large, independent, randomised, placebo-controlled, double-blind, prospective 3-year trials. Osteoporosis International, 13 (Suppl.3), 60. Peer Reviewed verified by ORBi |
Reginster, J.-Y., Rovati, L., Deroisy, R., Henrotin, Y., Gatterova, J., Machacek, S., Gonzalez, C., Giacovelli, G., & Pavelka, K. (June 2002). Glucosamine sulfate slows-down osteoarthritis progression in postmenopausal women: pooled analysis of two large, independent, randomised, placebo-controlled, double-blind, prospective 3-year trials. Annals of the Rheumatic Diseases, 61 (Suppl.1). Peer Reviewed verified by ORBi |
Pavelka, K., Rovati, L. C., Gatterova, J., Bruyère, O., Deroisy, R., Machacek, S., Giacovelli, G., Gonzalez, C., & Reginster, J.-Y. (June 2002). Pain relief is not a confounder in joint space narrowing assessment of full extension knee radiographs. Annals of the Rheumatic Diseases, 61 (Suppl.1), 118. Peer Reviewed verified by ORBi |
Reginster, J.-Y., Henrotin, Y., Deroisy, R., Giacovelli, G., Gonzalez, C., & Rovati, L. (June 2002). Correlation between mean and minimum joint space measurements in a long-term trial with glucosamine sulfate, an osteoarthritis modifying agent. Annals of the Rheumatic Diseases, 61 (Suppl.1). Peer Reviewed verified by ORBi |
Deroisy, R., Collette, J., Albert, A., Jupsin, I., & Reginster, J.-Y. (February 2002). Administration of a supplement containing both calcium and vitamin D is more effective than calcium alone to reduce secondary hyperparathyroidism in postmenopausal women with low 25(OH)vitamin D circulating levels. Aging Clinical and Experimental Research, 14 (1), 13-17. doi:10.1007/BF03324412 Peer Reviewed verified by ORBi |
Pavelka, K., Rovati, L. C., Gatterova, J., Bruyère, O., DEROISY, R., Machacek, S., Giacovelli, G., Gonzalez, C., & Reginster, J.-Y. (2002). Pain relief is not a confounder in joint space narrowing assessment of full extension knee radiographs. Osteoarthritis and Cartilage, 10 (SA), 16-17. Peer Reviewed verified by ORBi |
Ben Sedrine, W., Devogelaer, J. P., Kaufman, J. M., Goemaere, S., Depresseux, G., Zegels, B., Deroisy, R., & Reginster, J.-Y. (October 2001). Evaluation of the Simple Calculated Osteoporosis Risk Estimation (Score) in a Sample of White Women from Belgium. BONE, 29 (4), 374-80. doi:10.1016/S8756-3282(01)00583-X Peer Reviewed verified by ORBi |
DEROISY, R., Collette, J., Albert, A., JUPSIN, I., & Reginster, J.-Y. (2001). Supplementation with a calcium-vitamin D association is more efficient than calcium alone to reduce secondary hyperparathyroidism in postmenopausal women with low 25(OH) vitamin D circulating levels. Clinical Rheumatology, 20, 424. Peer Reviewed verified by ORBi |
Ben Sedrine, W., Devogelaer, J., Kaufman, J., Goemaere, S., Depresseux, G., Zegels, B., DEROISY, R., & Reginster, J.-Y. (2001). Evaluation of the simple calculated osteoporosis risk estimation in a sample of Caucasian women from Belgium. Clinical Rheumatology, 20, 420. Peer Reviewed verified by ORBi |
Reginster, J.-Y., Deroisy, R., Rovati, L. C., Lee, R. L., Lejeune, E., Bruyère, O., Giacovelli, G., Henrotin, Y., Dacre, J. E., & Gosset, C. (January 2001). Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. The Lancet, 357, 251-256. doi:10.1016/S0140-6736(00)03610-2 Peer Reviewed verified by ORBi |
Reginster, J.-Y., COLLETTE, J., Bruyère, O., Rovati, L. C., Giacovelli, G., DEROISY, R., Seidel, L., & Henrotin, Y. (2001). Short term (1-year) changes in keratan sulfate levels predict long-term (3-year) radiological evolution of knee osteoarthritis in patients treated with glucosamine sulfate. Arthritis and Rheumatism, 44 (Suppl.1), 139. Peer Reviewed verified by ORBi |
Reginster, J.-Y., COLLETTE, J., Bruyère, O., Rovati, L. C., Giacovelli, G., DEROISY, R., Seidel, L., & Henrotin, Y. (2001). Short term (1-year) changes in keratan sulfate levels predict long-term (3-year) radiological evolution of knee osteoarthritis in patients treated with glucosamine sulfate. Osteoarthritis and Cartilage, 9 (Suppl.B), 35. Peer Reviewed verified by ORBi |
DEROISY, R., Collette, J., Taquet, A., Thines, F., & Reginster, J.-Y. (2001). Comparison of the effect of combined calcium-vitamin D or calcium alone administration on circulating levels of parathyroid hormone (PTH) and 25-OH vitamin D (25-OHD) in ambulatory vitamin D-depleted post-menopausal women. BONE, S28, 231. Peer Reviewed verified by ORBi |
Reginster, J.-Y., Zegels, B., DEROISY, R., Lejeune, E., & Taquet, A. (2001). The timing, dose and choice of calcium and vitamin D. BONE, S28, 253. Peer Reviewed verified by ORBi |
Reginster, J.-Y., DEROISY, R., Tsouderos, Y., JUPSIN, I., & Roux, C. (2001). Prevention of early postmenopausal bone loss by strontium ranelate : a randomised, two-year, double-blind, placebo-controlled trial. Journal of Bone and Mineral Research, 16 (S1), 219. Peer Reviewed verified by ORBi |
Reginster, J.-Y., DEROISY, R., Lee, R., Rovati, L., Lejeune, E., Giacovelli, G., Henrotin, Y., Dacre, J., & Gosset, C. (2000). Long-term disease modifying effect by glucosamine sulfate in knee osteoarthritis : relationship between structure and symptom changes. Annals of the Rheumatic Diseases, 59 (S1), 55. Peer Reviewed verified by ORBi |
Reginster, J.-Y., COLLETTE, J., Rovati, L. C., DEROISY, R., Bruyère, O., & Henrotin, Y. (2000). Changes in serum osteocalcin but not other serum and urinary markers of bone and cartilage metabolism, measured after 12 months, are significantly correlated to long-term (36 monts) structural changes in knee osteoarthritis. Arthritis and Rheumatism, 43 (Suppl.1), 398. Peer Reviewed verified by ORBi |
Reginster, J.-Y., COLLETTE, J., Rovati, L. C., DEROISY, R., Honore, A., Bruyère, O., Seidel, L., & Henrotin, Y. (2000). Biochemical markers of bone and cartilage remodeling are poorly correlated with clinical and radiological severity of knee osteoarthritis. Arthritis and Rheumatism, 43 (Suppl.1), 339. Peer Reviewed verified by ORBi |
Reginster, J.-Y., DEROISY, R., Paul, I., Lee, R., Giacovelli, G., Dacre, J., Rovati, L., & Gosset, C. (2000). Glucosamine sulfate significantly reduces progression of knee osteoarthritis over 3 years : a large randomized, placebo-controlled, double-blind, prospective trial. Osteoarthritis and Cartilage, 8, 151. Peer Reviewed verified by ORBi |
Christgau, S., Henrotin, Y., Enriksen, D., Rovati, L., Collette, J., DEROISY, R., Christiansen, C., & Reginster, J.-Y. (2000). Cartilage degradation in knee osteoarthritis patients with elevated levels of urinary collagen type II C-telopeptide fragments. Arthritis and Rheumatism, 43 (S1), 1243. Peer Reviewed verified by ORBi |
Reginster, J.-Y., Deroisy, R., Paul, I., Hansenne, M., & Ansseau, M. (1999). Depressive vulnerability is not an independent risk factor for osteoporosis in postmenopausal women. Maturitas, 33 (2), 133-7. doi:10.1016/S0378-5122(99)00057-2 Peer Reviewed verified by ORBi |
Reginster, J.-Y., DEROISY, R., Paul, I., Lee, R., Henrotin, Y., Giacovelli, G., Dacre, J., Rovati, L., & Gosset, C. (1999). Glucosamine sulfate significantly reduces progression of the knee osteoarthritis over 3 years : a large randomised, placebo-controlled, double-blind, prospective trial. Arthritis and Rheumatism, 42 (S1), 400. Peer Reviewed verified by ORBi |
Reginster, J.-Y., Deroisy, R., Pirenne, H., Frederick, I., Dewé, W., Albert, A., Collette, J., Zheng, S. X., & Gosset, C. (1999). High Prevalence of Low Femoral Bone Mineral Density in Elderly Women Living in Nursing Homes or Community-Dwelling: A Plausible Role of Increased Parathyroid Hormone Secretion. Osteoporosis International, 9 (2), 121-8. doi:10.1007/s001980050124 Peer Reviewed verified by ORBi |
DEROISY, R., Taquet, A., Dewe, W., Albert, A., Collette, J., Gosset, C., & Reginster, J.-Y. (1998). Parathyroid hormone plasma concentration in response to low 25-OH vitamin D circulating levels increase with age in elderly women. Osteoporosis International, 8 (S3), 40. Peer Reviewed verified by ORBi |
DEROISY, R., Collette, J., Chevalier, T., Breuil, V., & Reginster, J.-Y. (1998). Effects of two 1-year calcium and vitamin D3 treatments on bone remodeling markers and femoral bone density in elderly women. Current Therapeutic Research, 59 (12), 850-862. doi:10.1016/S0011-393X(98)85050-9 Peer Reviewed verified by ORBi |
Reginster, J.-Y., Frederick, I., Deroisy, R., Dewe, W., Taquet, A. N., Albert, A., Collette, J., Pirenne, H., Zheng, S. X., & Gosset, C. (1998). Parathyroid hormone plasma concentrations in response to low 25-OH vitamin D circulating levels increases with age in elderly women. Osteoporosis International, 8 (4), 390-2. doi:10.1007/s001980050080 Peer Reviewed verified by ORBi |
Deroisy, R., Collette, J., Dewe, W., Albert, A., Gosset, C., & Reginster, J.-Y. (1998). Increased parathyroïd hormone secretions as a risk factor for femoral osteoporosis in elderly women. Osteoporosis International, 8 (S3), 40. Peer Reviewed verified by ORBi |
DEROISY, R., Collette, J., Albert, A., Leber, C., Micheletti, M., Zartarian, M., & Reginster, J.-Y. (1998). Comparison of the short-term effects of three oral calcium vitamin D formulations and placebo on calcium metabolism. Current Therapeutic Research, 59 (6), 370-378. doi:10.1016/S0011-393X(98)85039-X Peer Reviewed verified by ORBi |
Reginster, J.-Y., Albert, A., Deroisy, R., Collette, J., Vrijens, B., Blacker, C., Brion, N., Caulin, F., Mayolle, C., Regnard, A., Scholler, R., & Franchimont, P. (June 1997). Plasma Estradiol Concentrations and Pharmacokinetics Following Transdermal Application of Menorest 50 or Systen (Evorel) 50. Maturitas, 27 (2), 179-86. doi:10.1016/S0378-5122(97)00027-3 Peer Reviewed verified by ORBi |
Deroisy, R., Zartarian, M., Meurmans, L., Nelissenne, N., Micheletti, M. C., Albert, A., & Reginster, J.-Y. (May 1997). Acute Changes in Serum Calcium and Parathyroid Hormone Circulating Levels Induced by the Oral Intake of Five Currently Available Calcium Salts in Healthy Male Volunteers. Clinical Rheumatology, 16 (3), 249-53. doi:10.1007/BF02238959 Peer Reviewed verified by ORBi |
Reginster, J.-Y., Deroisy, R., Collette, J., Albert, A., & Zegels, B. (March 1997). Prediction of Bone Loss Rate in Healthy Postmenopausal Women. Calcified Tissue International, 60 (3), 261-4. doi:10.1007/s002239900226 Peer Reviewed verified by ORBi |
Reginster, J.-Y., Deroisy, R., Zegels, B., Denis, D., Reginster-Haneuse, G., Wilkin, P., Taziaux, P., Albert, A., & Boelen, C. (1997). Prévention de l'ostéoporose à Liège. Evaluation d'un essai de partenariat entre médecins généralistes et spécialistes universitaires (1). Revue Médicale de Liège, 52 (1), 31-36. Peer reviewed |
Reginster, J.-Y., Halkin, V., Gosset, C., & Deroisy, R. (1997). The role of bisphosphonates in the treatment of osteoporosis. Drugs of Today, 33, 563-570. Peer reviewed |
Deroisy, R., Pirenne, H., FREDERICK, I., Zegels, B., Taquet, A., Noel, V., Albert, A., & Reginster, J.-Y. (1996). Densité osseuse fémorale et carence vitaminique D dans une population de femmes âgées. Archives of Public Health, 53 (S1), 37. Peer Reviewed verified by ORBi |
DEROISY, R., Zheng, X., Pirenne, H., Frederick, I., COLLETTE, J., & Reginster, J.-Y. (1996). 25-OH vitamin D deficiencies and secondary hyperparathyroidism in elderly women living at home or in nursing/retirement homes. Osteoporosis International, 6 (S1), 119. Peer Reviewed verified by ORBi |
Roux, C., DEROISY, R., Basse-Cathalinat, B., Combe, B., Geusens, P., Meunier, P., Ribot, C., Rossi, M., Sebert, J., Bonvoisin, B., Listrat, V., & Reginster, J.-Y. (1996). Prevention of early postmenopausal bone loss with oral tiludronate. Osteoporosis International, 6 (S1), 249. Peer Reviewed verified by ORBi |
Reginster, J.-Y., Albert, A., Deroisy, R., Collette, J., Vrijens, B., Blacker, C., Brion, N., Caulin, F., Mayolle, C., Regnard, A., Sholler, R., & Franchimont, P. (1996). Plasma Concentration of Estradiol Following Transdermal Administration of Systen 50 or Menorest 50. Scandinavian Journal of Rheumatology. Supplement, 103, 94-8, discussion 99-100. doi:10.3109/03009749609103761 Peer Reviewed verified by ORBi |
DEROISY, R., Zheng, X., Pirenne, H., Frederick, I., & Reginster, J.-Y. (1996). Femoral osteoporosis in community-dwelling elderly females and controls living in retirement or nursing homes. Osteoporosis International, 6 (S1), 118. Peer Reviewed verified by ORBi |
DEROISY, R., Albert, A., Zheng, S., COLLETTE, J., & Reginster, J.-Y. (1996). 25-OH vitamin D levels in healthy ambulatory postmenopausal women. Osteoporosis International, 6 (S1), 119. Peer Reviewed verified by ORBi |
Reginster, J.-Y., DEROISY, R., LECART, M.-P., Zegels, B., Denis, D., SARLET, N., Reginster-Haneuse, G., Albert, A., & Boelen, C. (1996). Prévention de l’ostéoporose à Liège. Histoire d’un PIGEPS : dix ans plus tard. Santé Publique: Revue Multidisciplinaire pour la Recherche et l'Action, 2, 139-150. Peer Reviewed verified by ORBi |
Reginster, J.-Y., Jupsin, I., Deroisy, R., Biquet, I., Franchimont, N., & Franchimont, P. (June 1995). Prevention of Postmenopausal Bone Loss by Rectal Calcitonin. Calcified Tissue International, 56, 539-42. doi:10.1007/BF00298586 Peer Reviewed verified by ORBi |
Reginster, J.-Y., Deroisy, R., Lecart, M. P., Sarlet, N., Zegels, B., Jupsin, I., de Longueville, M., & Franchimont, P. (May 1995). A Double-Blind, Placebo-Controlled, Dose-Finding Trial of Intermittent Nasal Salmon Calcitonin for Prevention of Postmenopausal Lumbar Spine Bone Loss. American Journal of Medicine, 98 (5), 452-8. doi:10.1016/S0002-9343(99)80344-1 Peer Reviewed verified by ORBi |
Reginster, J.-Y., Deroisy, R., Zegels, B., Jupsin, I., Albert, A., & Franchimont, P. (March 1995). Long-Term Performance in Vitro and in Vivo of Dual-Energy X-Ray Absorptiometry. Clinical Rheumatology, 14 (2), 180-6. doi:10.1007/BF02214940 Peer Reviewed verified by ORBi |
Reginster, J.-Y., DEROISY, R., & Franchimont, P. (1995). De réels progrès ont-ils été faits dans le traitement de l'ostéoporose ? Medi-Sphere, 39, 7-14. Peer reviewed |
Deroisy, R., Pirenne, H., Frederick, I., Zegels, B., Taquet, A., Noel, V., Zheng, Z., & Reginster, J.-Y. (1995). Densité osseuse fémorale et carence vitaminique D dans une population de femmes âgées. Revue du Rhumatisme, 10, 763. Peer Reviewed verified by ORBi |
Deroisy, R., Pirenne, H., Frederick, I., Zegels, B., Taquet, A., Noel, V., Zheng, Z., & Reginster, J.-Y. (1995). Femoral bone density and vitamin D deficiency in elderly women. Archives of Public Health, 52 (S1), 81. Peer Reviewed verified by ORBi |
Reginster, J.-Y., Janssen, C., DEROISY, R., Zegels, B., Albert, A., & FRANCHIMONT, P. (1995). Bone mineral density of the spine and the hip measured with dual energy X-ray absorptiometry: normal range and fracture threshold for western European (Belgian) postmenopausal females. Clinical Rheumatology, 14 (1), 68-75. doi:10.1007/BF02208087 Peer Reviewed verified by ORBi |
DEROISY, R., Zartarian, M., Meurmans, L., Albert, A., Franchimont, P., & Reginster, J.-Y. (1995). Comparison of calcium absorption measured by changes in serum calcium and parathormone, after oral acute administration of 500 mg calcium from five different calcium salts compared with a placebo. BONE, 16 (S1), 98. Peer Reviewed verified by ORBi |
Deroisy, R., Pirenne, H., Frederick, I., Zegels, B., Taquet, A., Noel, V., Zheng, Z., & Reginster, J.-Y. (1995). Femoral bone density and vitamin D deficiency in elderly women. Journal of Bone and Mineral Research, 10 (S1), 463. Peer Reviewed verified by ORBi |
Reginster, J.-Y., Deroisy, R., & Franchimont, P. (15 December 1994). Traitement de l'ostéoporose: données actuelles et perspectives. Revue du Rhumatisme, 61 (10, Pt 2), 155S-164. Peer Reviewed verified by ORBi |
Reginster, J.-Y., Meurmans, L., Deroisy, R., Jupsin, I., Biquet, I., Albert, A., & Franchimont, P. (August 1994). A 5-Year Controlled Randomized Study of Prevention of Postmenopausal Trabecular Bone Loss with Nasal Salmon Calcitonin and Calcium. European Journal of Clinical Investigation, 24 (8), 565-9. doi:10.1111/j.1365-2362.1994.tb01108.x Peer Reviewed verified by ORBi |
Reginster, J.-Y., Denis, D., Bartsch, V., DEROISY, R., Zegels, B., & Franchimont, P. (1994). Acute biochemical variations induced by four different calcium salts in healthy male volunteers. Equilibre, 19, 5. Peer reviewed |
Reginster, J.-Y., Denis, D., Deroisy, R., Lecart, M. P., De Longueville, M., Zegels, B., Sarlet, N., Noirfalisse, P., & Franchimont, P. (January 1994). Long-Term (3 Years) Prevention of Trabecular Postmenopausal Bone Loss with Low-Dose Intermittent Nasal Salmon Calcitonin. Journal of Bone and Mineral Research, 9 (1), 69-73. doi:10.1002/jbmr.5650090110 Peer Reviewed verified by ORBi |
Reginster, J.-Y., DEROISY, R., & Franchimont, P. (1994). De réels progrès ont-ils été faits dans le traitement de l'ostéoporose ? Medisearch, 81, 39-45. Peer reviewed |
Reginster, J.-Y., DEROISY, R., & Franchimont, P. (1994). De réels progrès ont-ils été faits dans le traitement de l'ostéoporose ? Les Nouvelles de Rhumatologie, 4, 3-8. Peer reviewed |
DEROISY, R., Zartarian, M., Meurmans, L., Albert, A., & Reginster, J.-Y. (1994). Comparaison de l'absorption de calcium, appréciée par la mesure des variations de la calcémie et de la parathormone sérique, après l'administration orale aiguë de 500 mg de calcium élément sous 5 formulations différentes de sels calciques, comparé à un placebo. Revue du Rhumatisme, 10, 669. Peer Reviewed verified by ORBi |
Reginster, J.-Y., Gaspar, S., Deroisy, R., Zegels, B., & Franchimont, P. (September 1993). Prevention of Osteoporosis with Nasal Salmon Calcitonin: Effect of Anti-Salmon Calcitonin Antibody Formation. Osteoporosis International, 3, 261-4. doi:10.1007/BF01623830 Peer Reviewed verified by ORBi |
Reginster, J.-Y., Denis, D., Bartsch, V., Deroisy, R., Zegels, B., & Franchimont, P. (September 1993). Acute Biochemical Variations Induced by Four Different Calcium Salts in Healthy Male Volunteers. Osteoporosis International, 3, 271-5. doi:10.1007/BF01623832 Peer Reviewed verified by ORBi |
Reginster, J.-Y., Christiansen, C., Dequinze, B., Deroisy, R., Gaspard, U., Taquet, A. N., & Franchimont, P. (July 1993). Effect of Transdermal 17 Beta-Estradiol and Oral Conjugated Equine Estrogens on Biochemical Parameters of Bone Resorption in Natural Menopause. Calcified Tissue International, 53, 13-6. doi:10.1007/BF01352008 Peer Reviewed verified by ORBi |
Reginster, J.-Y., Meurmans, L., Zegels, B., Darte, C., COLLETTE, J., DEROISY, R., & Franchimont, P. (1993). New radioimmunoassay for determination of bone specific iso-enzymes of serum alkaline phosphatases activity (Ostase°): validation and clinical perspective. Journal of Bone and Mineral Research, 8 (S1), 261. Peer Reviewed verified by ORBi |
Reginster, J.-Y., DEROISY, R., LECART, M.-P., Zegels, B., Sarlet, N., de Longueville, M., Albert, A., & Franchimont, P. (1993). Nasal salmon calcitonin for prevention of early postmenopausal bone loss: a dose-ranging placebo controlled study. Journal of Bone and Mineral Research, 8 (S1), 340. Peer Reviewed verified by ORBi |
Reginster, J.-Y., Lecart, M.-P., Deroisy, R., Ethgen, D., Zegels, B., & Franchimont, P. (January 1993). Paget's Disease of Bone Treated with a Five Day Course of Oral Tiludronate. Annals of the Rheumatic Diseases, 52 (1), 54-7. doi:10.1136/ard.52.1.54 Peer Reviewed verified by ORBi |
Reginster, J.-Y., Sarlet, N., Deroisy, R., Albert, A., Gaspard, U., & Franchimont, P. (November 1992). Minimal Levels of Serum Estradiol Prevent Postmenopausal Bone Loss. Calcified Tissue International, 51, 340-3. doi:10.1007/BF00316876 Peer Reviewed verified by ORBi |
Reginster, J.-Y., Deroisy, R., Bruwier, M., & Franchimont, P. (May 1992). Calcitonin Metabolism in Senile (Type II) Osteoporosis. Osteoporosis International, 2, 141-5. doi:10.1007/BF01623821 Peer Reviewed verified by ORBi |
Reginster, J.-Y., Deroisy, R., Fontaine, M. A., & Franchimont, P. (March 1992). Influence of Estrogen Replacement Therapy on Endogenous Calcitonin Production Rates. Gynecological Endocrinology, 6 (1), 65-71. doi:10.3109/09513599209081008 Peer Reviewed verified by ORBi |
Reginster, J.-Y., Sarlet, N., Albert, A., DEROISY, R., & Franchimont, P. (1992). Estrogen replacement therapy and inhibition of bone resorption. Revue du Rhumatisme et des Maladies Osteo-Articulaires, 59, 528. Peer Reviewed verified by ORBi |
Reginster, J.-Y., Ethgen, D., DEROISY, R., & Franchimont, P. (1992). Evidence that oral tiludronate is a first line prevention of postmenopausal osteoporosis. Revue du Rhumatisme et des Maladies Osteo-Articulaires, 59, 528. Peer Reviewed verified by ORBi |
Reginster, J.-Y., Denis, D., Bartsch, V., DEROISY, R., & Franchimont, P. (1992). Comparison of acute biochemical variations induced by ingestion of different calcium salts in healthy volunteers. Revue du Rhumatisme et des Maladies Osteo-Articulaires, 59, 526. Peer Reviewed verified by ORBi |
Reginster, J.-Y., DEROISY, R., Sarlet, N., & Franchimont, P. (1992). Relation between calcium intake during different periods of life and bone mineral content at the menopause. Revue du Rhumatisme et des Maladies Osteo-Articulaires, 59, 527. Peer Reviewed verified by ORBi |
Reginster, J.-Y., DEROISY, R., Zegels, B., Lecart, M., Denis, D., & Franchimont, P. (1992). Intérêts et limites de l'absorptiométrie biphotonique dans le dépistage de l'ostéoporose postménopausique. Revue du Rhumatisme et des Maladies Osteo-Articulaires, 59, 511. Peer Reviewed verified by ORBi |
Lecart, M., Reginster, J.-Y., DEROISY, R., Sarlet, N., Ethgen, D., & Franchimont, P. (1992). Treatment of Paget’s disease of bone with high doses of oral tiludronate given during a five-day course therapy. Revue du Rhumatisme et des Maladies Osteo-Articulaires, 59, 526. Peer Reviewed verified by ORBi |
Reginster, J.-Y., Lecart, M., DEROISY, R., Sarlet, N., Albert, A., & Franchimont, P. (1992). Normal values for lumbar and femoral bone mineral density in Western European postmenopausal females, comparison of dual photon absorptiometry and quantitative digital radiography. Revue du Rhumatisme et des Maladies Osteo-Articulaires, 59, 527. Peer Reviewed verified by ORBi |
Reginster, J.-Y., DEROISY, R., Sarlet, N., Albert, A., Lecart, M., & Franchimont, P. (1992). Bone mineral content of lumbar spine and hip in a normal european female population: comparison of dual photon absorptiometry and quantitative digital radiology. Revue du Rhumatisme et des Maladies Osteo-Articulaires, 59, 528. Peer Reviewed verified by ORBi |
Reginster, J.-Y., DEROISY, R., Albert, A., Taquet, A., Jupsin, I., Denis, D., & Franchimont, P. (1992). Long term (3 years) prevention of trabecular postmenopausal bone loss with low dose intermittent nasal salmon calcitonin. Revue du Rhumatisme et des Maladies Osteo-Articulaires, 59, 527. Peer Reviewed verified by ORBi |
Reginster, J.-Y., DEROISY, R., Albert, A., Sarlet, N., & Franchimont, P. (1992). Long-term precision of quantitative digital radiology. Revue du Rhumatisme et des Maladies Osteo-Articulaires, 59, 527. Peer Reviewed verified by ORBi |
Reginster, J.-Y., DEROISY, R., & Franchimont, P. (1991). Effects of different calcium formulations on calcium absorption in healthy volunteers. Advances in Therapy, 8 (2), 86-91. Peer Reviewed verified by ORBi |
Reginster, J.-Y., DEROISY, R., Sarlet, N., & Franchimont, P. (1991). Nasal salmon calcitonin in prevention of postmenopausal osteoporosis. Revista Clinica Espanola, 188, 46-48. Peer Reviewed verified by ORBi |
Reginster, J.-Y., Ethgen, D., DEROISY, R., & Franchimont, P. (1991). Evidence that oral tiludronate is a first line prevention of post-menopausal osteoporosis. Calcified Tissue International, 48, 153. Peer Reviewed verified by ORBi |
Reginster, J.-Y., Denis, D., Deroisy, R., Albert, A., Sarlet, N., Collette, J., & Franchimont, P. (June 1990). Dual Photon Absorptiometry of Lumbar Spine in West European (Belgian) Postmenopausal Females: Normal Range and Fracture Threshold. Clinical Rheumatology, 9 (2), 220-4. doi:10.1007/BF02031972 Peer Reviewed verified by ORBi |
Reginster, J.-Y., DEROISY, R., Lecart, M., Ethgen, D., & Franchimont, P. (1990). Prevention of postmenopausal bone loss by tiludronate. Japanese Journal of Bone and Metabolism, 8, 289. Peer reviewed |
Reginster, J.-Y., Gennari, C., Mautalen, C., Deroisy, R., Denis, D., Lecart, M. P., Vandalem, J. L., Collette, J., & Franchimont, P. (1990). Influence of Specific Anti-Salmon Calcitonin Antibodies on Biological Effectiveness of Nasal Salmon Calcitonin in Paget's Disease of Bone. Scandinavian Journal of Rheumatology, 19 (1), 83-6. doi:10.3109/03009749009092626 Peer Reviewed verified by ORBi |
Reginster, J.-Y., Lecart, M., DEROISY, R., SARLET, N., Ethgen, D., & Franchimont, P. (1990). Treatment of Paget's disease of bone with high doses of oral tiludronate given during a five-day course therapy. Journal of Bone and Mineral Research, 5 (S2), 170. Peer Reviewed verified by ORBi |
Reginster, J.-Y., Lecart, M., DEROISY, R., SARLET, N., Denis, D., Albert, A., COLLETTE, J., & Franchimont, P. (1990). Prevention of postmenopausal bone loss by tiludronate. Menopause Digest, 4, 28. Peer reviewed |
Reginster, J.-Y., DEROISY, R., Lecart, M., SARLET, N., Fontaine, M., Albert, A., & Franchimont, P. (1990). Calcitonin and Postmenopausal Bone Loss. Experimental Gerontology, 25, 349-56. doi:10.1016/0531-5565(90)90072-A Peer Reviewed verified by ORBi |
Reginster, J.-Y., Almer, S., Gaspar, S., Albert, A., Deroisy, R., & Franchimont, P. (June 1989). Hypocalcémie induite chez le sujet pagétique par la calcitonine salmine nasale. Effets des anticorps anti-calcitonine salmine. Revue du Rhumatisme et des Maladies Osteo-Articulaires, 56 (7), 563-7. Peer Reviewed verified by ORBi |
Reginster, J.-Y., Deroisy, R., Albert, A., Denis, D., Lecart, M.-P., Collette, J., & Franchimont, P. (March 1989). Relationship between Whole Plasma Calcitonin Levels, Calcitonin Secretory Capacity, and Plasma Levels of Estrone in Healthy Women and Postmenopausal Osteoporotics. Journal of Clinical Investigation, 83 (3), 1073-7. doi:10.1172/JCI113950 Peer Reviewed verified by ORBi |
Reginster, J.-Y., DEROISY, R., Denis, D., Lecart, M., Sarlet, N., & Franchimont, P. (1989). Calcitonin for prevention of postmenopausal bone loss: rational and results. European Journal of Clinical Investigation, 19, 88. Peer Reviewed verified by ORBi |
Reginster, J.-Y., Sarlet, N., DEROISY, R., Lecart, M., GASPARD, U., Albert, A., & Franchimont, P. (1989). Comparison of serum estrone levels, urinary calcium and urinary hydroxyproline in eugonadal and postmenopausal women with or without estrogen replacement therapy. Journal of Bone and Mineral Research, 4 (S1), 291. Peer Reviewed verified by ORBi |
Reginster, J.-Y., Lecart, M., Fontaine, M., DEROISY, R., & Franchimont, P. (1989). Corticostéroides et tissu osseux. Revue Médicale de Liège, 10, 365-373. Peer reviewed |
Reginster, J.-Y., DEROISY, R., Denis, D., Lecart, M., & Franchimont, P. (1989). Salmon calcitonin: state of the art in prevention of postmenopausal bone loss. Journal Belge de Médecine Physique et de Réhabilitation, 12, 41-46. Peer Reviewed verified by ORBi |
Reginster, J.-Y., DEROISY, R., Denis, D., Lecart, M., & Franchimont, P. (1989). Salmon calcitonin : state of the art in prevention of postmenopausal bone loss ? Acta Belgica. Medica Physica, 12, 41-46. Peer Reviewed verified by ORBi |
Sarlet, N., Reginster, J.-Y., GASPARD, U., DEROISY, R., Denis, D., Lecart, M., & Franchimont, P. (1989). Determination of minimal serum estradiol for prevention of postmenopausal bone loss. Calcified Tissue International, 44, 69. Peer Reviewed verified by ORBi |
Reginster, J.-Y., Strause, L., Deroisy, R., Lecart, M. P., Saltman, P., & Franchimont, P. (1989). Preliminary Report of Decreased Serum Magnesium in Postmenopausal Osteoporosis. Magnesium, 8 (2), 106-9. Peer Reviewed verified by ORBi |
Reginster, J.-Y., Lecart, M. P., Deroisy, R., Sarlet, N., Denis, D., Ethgen, D., Collette, J., & Franchimont, P. (1989). Prevention of Postmenopausal Bone Loss by Tiludronate. The Lancet, 2 (8678-8679, Dec 23-30), 1469-71. doi:10.1016/S0140-6736(89)92927-9 Peer Reviewed verified by ORBi |
Reginster, J.-Y., Lecart, M., DEROISY, R., Sarlet, N., Denis, D., Albert, A., COLLETTE, J., & Franchimont, P. (1989). Prevention of postmenopausal bone loss by intermittent oral bisphosphonate: Chloro-4-phenyl thiomethylene bisphosphonate: a one year double-blind study. Journal of Bone and Mineral Research, 4 (S1), 214. Peer Reviewed verified by ORBi |
Reginster, J.-Y., DEROISY, R., Lecart, M., & Franchimont, P. (1989). (Chloro-4-phenyl) thiomethylene bisphosphonate in Paget's bone disease. Journal Belge de Médecine Physique et de Réhabilitation, 12, 47-52. Peer Reviewed verified by ORBi |
Reginster, J.-Y., Sarlet, N., DEROISY, R., Denis, D., Lecart, M., & Franchimont, P. (1989). Comparaison de l'effet ostéoprotecteur des oestrogènes conjugués équins administrés par voie orale et du 17 beta-oestradiol percutané. Revue Médicale de Liège, 2, 55-60. Peer reviewed |
Denis, D., Lecart, M., DEROISY, R., JEUGMANS, A.-M., Albert, A., Reginster, J.-Y., & Franchimont, P. (1989). Un an de traitement de la maladie osseuse de Paget par spray nasal de calcitonine de saumon. Revue Médicale de Liège, 1, 23-27. Peer reviewed |
Reginster, J.-Y., Lecart, M., DEROISY, R., Sarlet, N., Denis, D., Albert, A., & Franchimont, P. (1989). Normal values for lumbar and femoral bone mineral density in western european postmenopausal females, comparison of dual photon absorptiometry and quantitative digital radiology. Journal of Bone and Mineral Research, 4 (S1), 290. Peer Reviewed verified by ORBi |
Lecart, M., Reginster, J.-Y., DEROISY, R., Denis, D., Sarlet, N., & Franchimont, P. (1989). Short-term therapy of Paget's disease of bone by increasing doses of a new bisphosphonate: chloro-4-thiomethylene bisphosphonate. Calcified Tissue International, 44, 87. Peer Reviewed verified by ORBi |
Reginster, J.-Y., DEROISY, R., Lecart, M., & Franchimont, P. (1989). (Chloro-4 phenyl) thiomethylene bisphosphonate in Paget’s bone disease. Acta Belgica. Medica Physica, 12, 47-52. Peer Reviewed verified by ORBi |
Reginster, J.-Y., Deroisy, R., Denis, D., Lecart, M. P., Sarlet, N., & Franchimont, P. (September 1988). Is There Any Place for Salmon Calcitonin in Prevention of Postmenopausal Bone Loss? Gynecological Endocrinology, 2 (3), 195-204. doi:10.3109/09513599809029344 Peer Reviewed verified by ORBi |
Reginster, J.-Y., Denis, D., Albert, A., DEROISY, R., Lecart, M., Fontaine, M., & Franchimont, P. (1988). Prevention of early postmenopausal bone loss by intranasal calcitonin - a controlled, randomised study lasting one year in normal women. Gynecological Endocrinology, 2, 21. Peer Reviewed verified by ORBi |
Reginster, J.-Y., DEROISY, R., Denis, D., & Franchimont, P. (1988). An estimation of the endogenous secretion of calcitonin in normal and pre and postmenopausal osteoporotic women. Gynecological Endocrinology, 2, 164. Peer Reviewed verified by ORBi |
Lecart, M., Denis, D., DEROISY, R., Reginster, J.-Y., & Franchimont, P. (1988). La maladie de Paget 100 ans après Sir Paget. Revue Médicale de Liège, 23, 765-784. Peer reviewed |
Lecart, M., Denis, D., DEROISY, R., Sarlet, N., Reginster, J.-Y., & Franchimont, P. (1988). L'ostéoporose postménopausique : un combat pour l'avenir. Contraception Fertilité Sexualité, 2, 23-32. Peer Reviewed verified by ORBi |
Reginster, J.-Y., DEROISY, R., & Franchimont, P. (1988). An estimation of the endogenous secretion of calcitonin in normal and pre and postmenopausal osteoporotic women. Journal of Bone and Mineral Research, 3 (S1), 159. Peer Reviewed verified by ORBi |
Reginster, J.-Y., Denis, D., Albert, A., Lismonde, S., Heynen, G., Deroisy, R., & Franchimont, P. (1988). Influence of the Nature of Calcium Salts on Serum Calcium, Phosphorus, Calcitonin, Growth Hormone, and Somatomedin C. Research in Experimental Medicine, 188, 131-7. doi:10.1007/BF01852269 Peer reviewed |
Reginster, J.-Y., JEUGMANS, A.-M., Albert, A., Denis, D., Deroisy, R., LECART, M.-P., Fontaine, M. A., Collette, J., & Franchimont, P. (1988). Biological and Clinical Assessment of a New Bisphosphonate, (Chloro-4 Phenyl) Thiomethylene Bisphosphonate, in the Treatment of Paget's Disease of Bone. BONE, 9 (6), 349-54. doi:10.1016/8756-3282(88)90115-9 Peer Reviewed verified by ORBi |
Lecart, M., JEUGMANS, A.-M., Albert, A., Denis, D., DEROISY, R., Fontaine, M., COLLETTE, J., Reginster, J.-Y., & Franchimont, P. (1988). Effets biologiques et cliniques d'un nouveau bisphosphonate (chloro-4-phényl) thiométhylène bisphosphonate dans la maladie osseuse de Paget. Revue Médicale de Liège, 24, 799-806. Peer reviewed |
Reginster, J.-Y., Denis, D., Albert, A., Deroisy, R., Lecart, M. P., Fontaine, M. A., Lambelin, P., & Franchimont, P. (26 December 1987). 1-Year Controlled Randomised Trial of Prevention of Early Postmenopausal Bone Loss by Intranasal Calcitonin. The Lancet, 2 (8574), 1481-3. doi:10.1016/S0140-6736(87)92619-5 Peer Reviewed verified by ORBi |